In antitrust suit, Hikma says Amarin locked up exclusive supply deals to shut out Vascepa generics

In the midst of Amarin’s activist investor blowout with Sarissa Capital Management, the company has a new battle brewing.

In a new antitrust suit, generics maker Hikma has accused Amarin of “deliberately and meticulously” locking up the supply icosapent ethyl in an attempt to block generic competition. Icosapent ethyl is the active ingredient in Amarin's only drug, Vascepa.